Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) Equity Average (2018 - 2021)

Cogent Biosciences (COGT) has 4 years of Equity Average data on record, last reported at $205.0 million in Q3 2021.

  • For Q3 2021, Equity Average rose 14080.29% year-over-year to $205.0 million; the TTM value through Sep 2021 reached $205.0 million, up 14080.29%, while the annual FY2020 figure was $133.2 million, 189.61% up from the prior year.
  • Equity Average reached $205.0 million in Q3 2021 per COGT's latest filing, down from $219.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $230.7 million in Q1 2021 and bottomed at -$1.5 million in Q3 2020.
  • Average Equity Average over 4 years is $79.9 million, with a median of $49.6 million recorded in 2019.
  • Peak YoY movement for Equity Average: crashed 104.29% in 2020, then skyrocketed 14080.29% in 2021.
  • A 4-year view of Equity Average shows it stood at $63.9 million in 2018, then crashed by 52.74% to $30.2 million in 2019, then soared by 251.9% to $106.2 million in 2020, then surged by 92.97% to $205.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for Equity Average were $205.0 million in Q3 2021, $219.8 million in Q2 2021, and $230.7 million in Q1 2021.